Companies: 10,795·Total market cap: $144.5T
Metsera, Inc.

Metsera, Inc.

MTSRNASDAQHealthcare
$70.50
$-0.25(-0.35%)
Market Cap$7.4B
P/E Ratio
52W High$83.8599
52W Low$12.3

Metsera, Inc. (MTSR) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

mtsr · pe ratio · data through Dec 31, 2024

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Metsera, Inc. (MTSR) measures how much investors pay for each dollar of the company's trailing earnings. MTSR's current PE ratio of N/A is calculated by dividing its stock price of $70.50 by its TTM earnings per share of -$2.99.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2024-12-31

Forward P/E
N/A
FY2026 est. EPS $-3.42
Based on 2 analysts
EPS (TTM)
-$2.99
TTM · diluted EPS
PEG Ratio
-9.83
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Metsera, Inc. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-08

PE Ratio History

2023 – 2024 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
Metsera, Inc.
Metsera, Inc.You
MTSR
$7.4BN/A-$2.99
Abivax S.A.
Abivax S.A.
ABVX
$6.8BN/A-$4.83
Arcellx, Inc.
Arcellx, Inc.
ACLX
$6.7BN/A-$4.07
Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc.
ARWR
$10.4BN/A-$0.01
Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc.
AXSM
$12.3BN/A-$3.68
CRISPR Therapeutics AG
CRISPR Therapeutics AG
CRSP
$5.0BN/A-$6.47
Cytokinetics, Incorporated
Cytokinetics, Incorporated
CYTK
$8.6BN/A-$6.54

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 2 of 2 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2024-12-31Latest
FY2024
$-2.03
2023-12-31
FY2023
$-0.95

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for Metsera, Inc. (MTSR) measures how much investors pay for each dollar of the company's trailing earnings. MTSR's current PE ratio of N/A is calculated by dividing its stock price of $70.50 by its TTM earnings per share of -$2.99.

PE Ratio = Stock Price ÷ EPS (TTM)
= $70.50 ÷ -$2.99 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

MTSR pe ratio · 6 questions

MTSR's current PE ratio is N/A as of 2026-06-08, based on a stock price of $70.50 and TTM EPS of -$2.99. Data sourced from Financial Modeling Prep via MTSR's SEC 10-K and 10-Q filings.

MTSR PE ratioWhat is MTSR PE ratioCurrent PE ratio of MTSRMTSR PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Metsera, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08